AKTX — Akari Therapeutics PLC
NASDAQ · Healthcare · Biotechnology
$10.20
-$0.17 (-1.64%)
Akari Therapeutics PLC (AKTX) is a biotechnology company listed on NASDAQ. It is led by Abizer Gaslightwala, based in 401 East Jackson Street, Tampa, FL, United States, 33602, with about 5 employees. Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Net income was -$6.4M. AKTX currently screens at market cap $17.2M.
Use this AKTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the AKTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the AKTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Akari Therapeutics PLC even when a live quote feed is slow.
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
AKTX Key Statistics
Market Cap
$17.25M
Volume
30,400
Previous Close
$7.47
Day Range
$7.69 – $8.10
EPS
$0.00
Revenue
$0.00
Net Income
-$19.79M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
5
AKTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2015 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$19.79M | -$10.01M | -$17.75M | -$45.32M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
Total Assets
$50.56M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$2.60M
Operating Cash Flow
-$12.55M
Free Cash Flow
$0.00
Akari Therapeutics PLC Company Information
- CEO, President & Director
- Abizer Gaslightwala
- Headquarters
- 401 East Jackson Street, Tampa, FL, United States, 33602
- Website
- www.akaritx.com
- Phone
- 929 274 7510
- IPO / Founded
- 2015-09-21
- Sector
- Healthcare
- Industry
- Biotechnology